Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi -- Ignore unavailable to you. Want to Upgrade?

To: Thomas who wrote (249)	7/10/2004 5:50:48 PM
From: tuck	Respond to of 671

More the latter, as the only thing they're talking about in detail is in vitro stuff. They're not the only ones using lipid conjugation, and it has its limitations. Perhaps they are addressing some of them. I'd have to run off to their website and track down some abstracts, etc. Don't have time for that now, as I'm back from a trip with a backlog of more important research and other stuff to do. So pick up that ball and run with it, if you're so inclined. Worth keeping an eye on them, as I hadn't heard of them before. Cheers, Tuck

To: Thomas who wrote (249)	7/10/2004 8:02:26 PM
From: tuck	Read Replies (1) \| Respond to of 671

Since you folow RNAI, the company . . . >>Atugen Strikes Contract Research Deal with Eisai Subsidiary By a GenomeWeb staff reporter NEW YORK, July 8 (GenomeWeb News) - Atugen said this week that it has signed a contract research agreement with Eisai London Research Laboratories, a subsidiary of Japanese drug maker Eisai. Under the deal, Atugen will use its gene-silencing technologies to validate and optimize undisclosed drug targets provided by Eisai. Additional terms, including the financials, were not disclosed. This is Atugen's second research agreement this year with a Japanese pharmaceutical company. The company also announced a multi-year agreement with Sankyo on May 17.<< Cheers, Tuck